@article{Wu2022, 
author = {Jingjing Wu and Fenghua Gao and Wenhua Wang and Xudong Zhang and Meng Dong and Lei Zhang and Xin Li and Ling Li and Zhenchang Sun and Xinhua Wang and Xiaorui Fu and Linan Zhu and Mengjie Ding and Songtao Niu and Zhaoming Li and Yu Chang and Feifei Nan and Jiaqian Yan and Hui Yu and Xiaolong Wu and Zhiyuan Zhou and Jieming Zhang and Mingzhi Zhang},
title = {Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase Ⅱ trial},
year = {2022},
journal = {Cancer Biology & Medicine},
volume = {19},
number = {7},
pages = {1089-1099},
keywords = {Rituximab, primary central nervous system lymphoma, pemetrexed, fotemustine, WBRT},
url = {https://www.sciopen.com/article/10.20892/j.issn.2095-3941.2021.0026},
doi = {10.20892/j.issn.2095-3941.2021.0026},
abstract = {ObjectiveThis study aimed to evaluate the safety, efficacy, and feasibility of the rituximab, fotemustine, pemetrexed, and dexamethasone (R-FPD) regimen followed by whole-brain radiotherapy (WBRT) for patients with primary central nervous system lymphoma (PCNSL).MethodsA prospective, single-center phase Ⅱ clinical trial was conducted. Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied. The R-FPD regimen consisted of rituximab (375 mg/m2 i.v. on D0), fotemustine (100 mg/m2 i.v. on D1), pemetrexed (600 mg/m2 i.v. on D1), and dexamethasone (40 mg i.v. on D1-5). Patients 60 years or younger who showed a complete response (CR) were treated with 23.4 Gy of WBRT after the end of chemotherapy; those older than 60 years with CR were treated with a wait-and-see approach; and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy + local tumor field irradiation up to 45 Gy, regardless of age.ResultsA total of 30 patients were included. After 2 cycles, the objective response rate (ORR) was 96.5% (28/29, 1 CR, 27 PR, 0 SD, and 1 PD). After 4 cycles, the ORR was 73.1% (19/26, 11 CR, 8 PR, 4 SD, and 3 PD). After WBRT, the ORR was 90.9% (10/11, 7 CR, 3 PR, and 1 SD). The grade Ⅲ and Ⅳ toxicity responses were mainly leukopenia (20.0%), thrombocytopenia (23.3%), and anemia (10.0%).ConclusionsFotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes, providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.}
}